Alterity Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Alterity Therapeutics's estimated annual revenue is currently $1.7M per year.
- Alterity Therapeutics's estimated revenue per employee is $188,889
- Alterity Therapeutics's total funding is $31.4M.
Employee Data
- Alterity Therapeutics has 9 Employees.
- Alterity Therapeutics grew their employee count by -36% last year.
Alterity Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Financial Officer | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | VP, Research and Nonclinical Development | Reveal Email/Phone |
4 | Senior Director, CMC | Reveal Email/Phone |
5 | Chief Financial Officer | Reveal Email/Phone |
6 | Clinical Project Manager | Reveal Email/Phone |
7 | Clinical Operations Consultant | Reveal Email/Phone |
8 | Senior Scientist Medicinal Chemsitry | Reveal Email/Phone |
9 | Senior Principal Research Scientist | Reveal Email/Phone |
10 | Senior Principal Scientist | Reveal Email/Phone |
Alterity Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $46.2M | 230 | 5% | N/A | N/A |
#2 | $43.8M | 218 | 21% | N/A | N/A |
#3 | $57.1M | 284 | 26% | N/A | N/A |
#4 | $24.5M | 122 | 3% | N/A | N/A |
#5 | $52.9M | 263 | 13% | N/A | N/A |
#6 | $24.7M | 123 | 13% | N/A | N/A |
#7 | $1.8M | 18 | 0% | $114.3M | N/A |
#8 | $7.2M | 36 | -20% | N/A | N/A |
#9 | $13.7M | 68 | -7% | N/A | N/A |
#10 | $7.6M | 39 | -13% | $123.9M | N/A |
What Is Alterity Therapeutics?
We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory for people with these debilitating diseases.
keywords:N/A
$31.4M
Total Funding
9
Number of Employees
$1.7M
Revenue (est)
-36%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Alterity Therapeutics News
2022-04-17 - Financial Analysis: Alterity Therapeutics (NASDAQ:ATHE) vs ...
Financial Analysis: Alterity Therapeutics (NASDAQ:ATHE) vs. International Stem Cell (OTCMKTS:ISCO). Posted by admin on Apr 16th, 2022.
2022-04-06 - AAN Spotlight: Multiple System Atrophy, Migraine, ALS and ...
Alterity Therapeutics presented new data from its ongoing Biomarkers of progression in Multiple System Atrophy (bioMUSE) study.
2022-04-06 - Alterity Therapeutics Announces Presentation of bioMUSE ...
MELBOURNE, Australia and SAN FRANCISCO, April 6, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH,NASDAQ: ATHE) ("Alterity" or "the...
Other Companies in Melbourne
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.7M | 9 | -65% | N/A |
#2 | $0.7M | 9 | N/A | N/A |
#3 | $0.7M | 9 | 0% | N/A |
#4 | $0.7M | 9 | -10% | N/A |
#5 | $0.7M | 9 | 0% | N/A |